Maximizing number of doses drawn from multi-dose COVID-19 vaccines by minimizing dead-volume
| Autor: | François Lesourd, Astrid Bacle, Brendan Le Daré, Roxane Lhermitte, Yves Lurton |
|---|---|
| Přispěvatelé: | Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Jonchère, Laurent, Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
2019-20 coronavirus outbreak
Medical device COVID-19 Vaccines Coronavirus disease 2019 (COVID-19) [SDV]Life Sciences [q-bio] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) SARS-COV-2 030204 cardiovascular system & hematology Vial 03 medical and health sciences 0302 clinical medicine Medicine Humans 030212 general & internal medicine Syringe extractable dose business.industry medical device Immunization Programs COVID-19 General Medicine medicine.disease Dead volume 3. Good health [SDV] Life Sciences [q-bio] Vaccination dead-volume Medical emergency business AcademicSubjects/MED00295 Vaccine Rapid Communication |
| Zdroj: | Journal of Travel Medicine Journal of Travel Medicine, 2021, 28 (4), pp.taab049. ⟨10.1093/jtm/taab049⟩ Journal of Travel Medicine, Wiley-Blackwell, 2021, 28 (4), pp.taab049. ⟨10.1093/jtm/taab049⟩ |
| ISSN: | 1708-8305 1195-1982 |
| DOI: | 10.1093/jtm/taab049⟩ |
| Popis: | International audience; The COVID-19 pandemic constitutes an unprecedented challenge to health care systems and societies worldwide. On 21 December 2020, the highly effective Pfizer–BioNTech COVID-19 vaccine was authorized in Europe, bringing big hopes for overcoming the pandemic.1 However, there are concerns about delayed availability of sufficient vaccine doses, forcing to prioritize target populations.2 Vaccination with the Pfizer–BioNTech COVID-19 vaccine consists of two doses (0.3 ml each) administered intramuscularly, 3 weeks apart. Each vial (2.25 ml theorical and 2.27 ml actual volume after dilution) meet the requirements of the European Pharmacopoeia allowing to obtain five doses using a syringe of a capacity not exceeding three times the volume to be measured and fitted with a 21-G needle not less than 2.5 cm in length.3 On 8 January 2021, European Medicines Agency announced that six doses could be extracted from a single vial using low dead-volume syringes and/or needles; i.e. no more than 35 μl for the syringe–needle combination.4 To date, no study has been carried out to propose recommendations on the use of adapted equipment. Here, we report the dead-volume of different syringe–needle combinations in order to inform such debate by relevant medical devices data. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|